Macquarie Group Ltd. grew its position in shares of Intrexon Corporation (NYSE:XON) by 25.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,995 shares of the biotechnology company’s stock after buying an additional 7,353 shares during the quarter. Macquarie Group Ltd.’s holdings in Intrexon were worth $684,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of XON. Tower Research Capital LLC TRC boosted its holdings in Intrexon by 2,031.7% in the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 4,937 shares during the last quarter. SG Americas Securities LLC bought a new position in Intrexon in the third quarter worth approximately $139,000. Federated Investors Inc. PA bought a new position in Intrexon in the second quarter worth approximately $172,000. Quantbot Technologies LP raised its position in shares of Intrexon by 423.7% during the 3rd quarter. Quantbot Technologies LP now owns 9,993 shares of the biotechnology company’s stock valued at $189,000 after purchasing an additional 8,085 shares during the period. Finally, Principal Financial Group Inc. bought a new stake in shares of Intrexon during the 2nd quarter valued at $212,000. Hedge funds and other institutional investors own 77.49% of the company’s stock.

A number of analysts have issued reports on XON shares. Northland Securities reiterated a “buy” rating and issued a $27.00 price target on shares of Intrexon in a report on Friday, October 6th. Griffin Securities reissued a “buy” rating and issued a $55.00 price objective on shares of Intrexon in a research note on Friday, October 6th. JMP Securities reaffirmed an “outperform” rating and set a $42.00 price target on shares of Intrexon in a research note on Thursday, October 5th. Zacks Investment Research cut shares of Intrexon from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, BidaskClub cut shares of Intrexon from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 22nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Intrexon has a consensus rating of “Hold” and an average target price of $38.50.

Intrexon Corporation (NYSE XON) traded down $0.26 during mid-day trading on Wednesday, hitting $12.73. 1,029,700 shares of the stock traded hands, compared to its average volume of 1,136,977. Intrexon Corporation has a fifty-two week low of $10.26 and a fifty-two week high of $29.39. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/13/intrexon-corporation-xon-stake-raised-by-macquarie-group-ltd.html.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).

Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Receive News & Stock Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related stocks with our FREE daily email newsletter.